Irinotecan Pathway, Pharmacokinetics

Overview
Components
Related Pathways
Associations
Related Literature
Downloads
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this pathway in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    25 items
    Literature
    Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
    Clinical pharmacokinetics. 2023. de With Mirjam, van Doorn Leni, Kloet Esmay, van Veggel Anne, Matic Maja, de Neijs Micha J, Oomen-de Hoop Esther, van Meerten Esther, van Schaik Ron H N, Mathijssen Ron H J and Bins Sander.
    PGx Paper Type: Drug-Gene Interaction for Pathway
    Literature
    Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
    Pharmacogenomics. 2016. Hattinger Claudia M, Vella Serena, Tavanti Elisa, Fanelli Marilù, Picci Piero and Serra Massimo.
    Literature
    ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Pharmacogenetics and genomics. 2015. Chen Sylvia, Villeneuve Lyne, Jonker Derek, Couture Félix, Laverdière Isabelle, Cecchin Erica, Innocenti Federico, Toffoli Giuseppe, Lévesque Eric and Guillemette Chantal.
    Literature
    S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
    British journal of cancer. 2013. Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y and Jung K H.
    Literature
    Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
    The Journal of pharmacology and experimental therapeutics. 2013. Lévesque Eric, Bélanger Anne-Sophie, Harvey Mario, Couture Félix, Jonker Derek, Innocenti Federico, Cecchin Erica, Toffoli Giuseppe and Guillemette Chantal.
    Literature
    Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
    British journal of clinical pharmacology. 2010. Sai Kimie, Saito Yoshiro, Tatewaki Naoko, Hosokawa Masakiyo, Kaniwa Nahoko, Nishimaki-Mogami Tomoko, Naito Mikihiko, Sawada Jun-Ichi, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Tamura Tomohide, Yamada Yasuhide, Ohe Yuichiro, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Matsumura Yasuhiro, Saijo Nagahiro and Okuda Haruhiro.
    Literature
    Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
    Journal of human genetics. 2009. Cha Pei-Chieng, Mushiroda Taisei, Zembutsu Hitoshi, Harada Hiromasa, Shinoda Noriyuki, Kawamoto Shunji, Shimoyama Rai, Nishidate Toshihiko, Furuhata Tomohisa, Sasaki Kazuaki, Hirata Koichi and Nakamura Yusuke.
    Literature
    Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    British journal of cancer. 2008. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, Laurand A, Poirier A-L, Morel A, Chatelut E, Robert J and Gamelin E.
    Literature
    Pharmacogenetic pathway analysis of irinotecan.
    Clinical pharmacology and therapeutics. 2008. Rosner G L, Panetta J C, Innocenti F and Ratain M J.
    Literature
    Haplotypes and a novel defective allele of CES2 found in a Japanese population.
    Drug metabolism and disposition: the biological fate of chemicals. 2007. Kim Su-Ryang, Sai Kimie, Tanaka-Kagawa Toshiko, Jinno Hideto, Ozawa Shogo, Kaniwa Nahoko, Saito Yoshiro, Akasawa Akira, Matsumoto Kenji, Saito Hirohisa, Kamatani Naoyuki, Shirao Kuniaki, Yamamoto Noboru, Yoshida Teruhiko, Minami Hironobu, Ohtsu Atsushi, Saijo Nagahiro and Sawada Jun-ichi.
    Literature
    Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
    Drug metabolism and disposition: the biological fate of chemicals. 2005. Nozawa Takashi, Minami Hironobu, Sugiura Shigeki, Tsuji Akira and Tamai Ikumi.
    Literature
    Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.
    Pharmacogenetics. 2003. Sai Kimie, Kaniwa Nahoko, Itoda Masaya, Saito Yoshiro, Hasegawa Ryuichi, Komamura Kazuo, Ueno Kazuyuki, Kamakura Shiro, Kitakaze Masafumi, Shirao Kuniaki, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Kitamura Yutaka, Kamatani Naoyuki, Ozawa Shogo and Sawada Jun-Ichi.
    Literature
    Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
    The Journal of pharmacology and experimental therapeutics. 2003. Jinno Hideto, Saeki Mayumi, Saito Yoshiro, Tanaka-Kagawa Toshiko, Hanioka Nobumitsu, Sai Kimie, Kaniwa Nahoko, Ando Masanori, Shirao Kuniaki, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Ozawa Shogo and Sawada Jun-ichi.
    Literature
    Irinotecan pathway genotype analysis to predict pharmacokinetics.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Mathijssen Ron H J, Marsh Sharon, Karlsson Mats O, Xie Rujia, Baker Sharyn D, Verweij Jaap, Sparreboom Alex and McLeod Howard L.
    Literature
    UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
    Pharmacogenetics. 2003. Desai Apurva A, Innocenti Federico and Ratain Mark J.
    Literature
    Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Cancer research. 2003. Rajendra Rajeev, Gounder Murugesan K, Saleem Ahamed, Schellens Jan H M, Ross Douglas D, Bates Susan E, Sinko Patrick and Rubin Eric H.
    Literature
    Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
    Molecular pharmacology. 2002. Gagné Jean-François, Montminy Valerie, Belanger Patrick, Journault Kim, Gaucher Genevieve and Guillemette Chantal.
    Literature
    UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    The pharmacogenomics journal. 2002. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming G F, Vokes E E, Schilsky R L and Ratain M J.
    Literature
    A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
    Drug metabolism and disposition: the biological fate of chemicals. 2001. Sai K, Kaniwa N, Ozawa S and Sawada J I.
    Literature
    Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2001. Mathijssen R H, van Alphen R J, Verweij J, Loos W J, Nooter K, Stoter G and Sparreboom A.
    Literature
    Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
    Clinical cancer research : an official journal of the American Association for Cancer Research. 2000. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse M L, Boige V, Gouyette A and Vassal G.
    Pediatric
    Literature
    ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
    Molecular pharmacology. 1999. Chen Z S, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K and Akiyama S I.
    Literature
    The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
    Cancer research. 1999. Morton C L, Wadkins R M, Danks M K and Potter P M.
    Literature
    Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    The Journal of pharmacology and experimental therapeutics. 1998. Dodds H M, Haaz M C, Riou J F, Robert J and Rivory L P.
    Literature
    Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    The Journal of clinical investigation. 1998. Iyer L, King C D, Whitington P F, Green M D, Roy S K, Tephly T R, Coffman B L and Ratain M J.